Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer Science|January 6, 2015
Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypesMisato Iizuka, Yoko Nakanishi, Fumi Fuchinoue, et al.
Toxicology|November 25, 2010
Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated miceJun Ozeki, Shigeyuki Uno, Michitaka Ogura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 27, 2012
[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis]Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 27, 2012
[Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer]Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 8, 2014
[Long-term response to eribulin in patients with metastatic breast cancer-report of 2 cases]Yukiko Hara, Kenichi Sakurai, Saki Nagashima, et al.
Breast Cancer Research and Treatment|September 24, 2022
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancerYuka Inoue, Makoto Fujishima, Makiko Ono, et al.
Breast Disease|December 5, 2025
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapyMeiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama, et al.
British Journal of Cancer|February 1, 2023
Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibilityKohei Kumegawa, Sumito Saeki, Yoko Takahashi, et al.
Cancer Medicine|February 19, 2025
Prognostic Impact of Stimulator of Interferon Genes Expression in Triple Negative Breast CancerTetsuyo Maeda, Makiko Ono, Tomo Osako, et al.
Breast Cancer (Tokyo, Japan)|December 7, 2024
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world studyYosuke Aoyama, Yukinori Ozaki, Rika Kizawa, et al.
Pageof 4